Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jerome Lewis Avorn, M.D.

Co-Author

This page shows the publications co-authored by Jerome Avorn and Sebastian Schneeweiss.
Connection Strength

10.785
  1. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.536
  2. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012 Jul 01; 5(4):480-6.
    View in: PubMed
    Score: 0.521
  3. Postmarketing studies of drug safety. BMJ. 2011 Feb 08; 342:d342.
    View in: PubMed
    Score: 0.473
  4. Managing drug-risk information--what to do with all those new numbers. N Engl J Med. 2009 Aug 13; 361(7):647-9.
    View in: PubMed
    Score: 0.425
  5. Imuunosuppressants, mortality, and risk of cancer. BMJ. 2009 Jul 03; 339:b1645.
    View in: PubMed
    Score: 0.423
  6. Antipsychotic agents and sudden cardiac death--how should we manage the risk? N Engl J Med. 2009 Jan 15; 360(3):294-6.
    View in: PubMed
    Score: 0.410
  7. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006 Apr; 79(4):379-88.
    View in: PubMed
    Score: 0.338
  8. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005 Apr; 58(4):323-37.
    View in: PubMed
    Score: 0.315
  9. Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction. Am J Cardiol. 2004 Aug 15; 94(4):415-20.
    View in: PubMed
    Score: 0.302
  10. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004 Mar 06; 328(7439):560.
    View in: PubMed
    Score: 0.292
  11. Pharmaceutical cost containment with reference-based pricing: time for refinements. CMAJ. 2002 Nov 26; 167(11):1250-1.
    View in: PubMed
    Score: 0.268
  12. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002 Jul; 58(4):285-91.
    View in: PubMed
    Score: 0.260
  13. Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2019 07 12; 74(8):1271-1276.
    View in: PubMed
    Score: 0.212
  14. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):980-987.
    View in: PubMed
    Score: 0.197
  15. Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018 01 01; 178(1):55-63.
    View in: PubMed
    Score: 0.191
  16. Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Saf. 2015 Sep; 38(9):845.
    View in: PubMed
    Score: 0.162
  17. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf. 2015 Jun; 38(6):565-75.
    View in: PubMed
    Score: 0.159
  18. Patients' preferences in anticoagulant therapy: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2014 Nov; 7(6):912-9.
    View in: PubMed
    Score: 0.153
  19. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30; 2(4):e000208.
    View in: PubMed
    Score: 0.140
  20. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e61-4.
    View in: PubMed
    Score: 0.132
  21. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012 Feb 23; 344:e977.
    View in: PubMed
    Score: 0.127
  22. Comment: generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother. 2012 Feb; 46(2):303-4; author reply 304.
    View in: PubMed
    Score: 0.126
  23. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011 Jul; 64(7):749-59.
    View in: PubMed
    Score: 0.118
  24. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf. 2010 Aug; 19(8):848-57.
    View in: PubMed
    Score: 0.114
  25. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010 Sep; 88(3):347-53.
    View in: PubMed
    Score: 0.114
  26. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010 Apr 14; 303(14):1401-9.
    View in: PubMed
    Score: 0.112
  27. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. J Ment Health Policy Econ. 2010 Mar; 13(1):37-44.
    View in: PubMed
    Score: 0.111
  28. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.109
  29. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009 Dec 08; 120(23):2322-9.
    View in: PubMed
    Score: 0.109
  30. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 Jul; 20(4):512-22.
    View in: PubMed
    Score: 0.106
  31. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.103
  32. The impact of cost sharing on antidepressant use among older adults in British Columbia. Psychiatr Serv. 2008 Apr; 59(4):377-83.
    View in: PubMed
    Score: 0.097
  33. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008 Jan; 26(1):145-53.
    View in: PubMed
    Score: 0.095
  34. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct; 45(10 Supl 2):S131-42.
    View in: PubMed
    Score: 0.094
  35. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007 Oct; 45(10 Supl 2):S158-65.
    View in: PubMed
    Score: 0.094
  36. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.
    View in: PubMed
    Score: 0.092
  37. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007 Jan 02; 115(1):27-33.
    View in: PubMed
    Score: 0.089
  38. Angiotensin inhibition after myocardial infarction: does drug class matter? J Gen Intern Med. 2006 Dec; 21(12):1242-7.
    View in: PubMed
    Score: 0.088
  39. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Dec; 54(12):3790-8.
    View in: PubMed
    Score: 0.088
  40. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.087
  41. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006 Dec; 65(12):1608-12.
    View in: PubMed
    Score: 0.086
  42. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006 Aug; 59(8):819-28.
    View in: PubMed
    Score: 0.085
  43. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.085
  44. Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006 May-Jun; 26(3):247-54.
    View in: PubMed
    Score: 0.085
  45. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005 Dec; 46(6):1080-7.
    View in: PubMed
    Score: 0.083
  46. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.082
  47. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May; 59(5):437-47.
    View in: PubMed
    Score: 0.082
  48. Statins and the risk of colorectal cancer. N Engl J Med. 2005 Sep 01; 353(9):952-4; author reply 952-4.
    View in: PubMed
    Score: 0.081
  49. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005 Aug; 62(8):1242-8.
    View in: PubMed
    Score: 0.081
  50. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005 Apr; 25(2):118-26.
    View in: PubMed
    Score: 0.079
  51. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.077
  52. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.077
  53. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004 Aug; 44(2):140-5.
    View in: PubMed
    Score: 0.075
  54. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med. 2004 May; 19(5 Pt 1):444-50.
    View in: PubMed
    Score: 0.074
  55. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.074
  56. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004 Apr; 14(4):296-303.
    View in: PubMed
    Score: 0.074
  57. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.072
  58. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003 Aug; 38(4):1103-20.
    View in: PubMed
    Score: 0.070
  59. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials. 2002 Dec; 23(6):757-73.
    View in: PubMed
    Score: 0.067
  60. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002 Jun; 22(3):236-43.
    View in: PubMed
    Score: 0.065
  61. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001 Nov 01; 154(9):854-64.
    View in: PubMed
    Score: 0.062
  62. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 11; 42(11):1287-1295.
    View in: PubMed
    Score: 0.054
  63. General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. Patient. 2019 04; 12(2):235-246.
    View in: PubMed
    Score: 0.052
  64. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
    View in: PubMed
    Score: 0.048
  65. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf. 2017 Jun; 26(6):712-721.
    View in: PubMed
    Score: 0.045
  66. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014 Nov; 127(11):1075-1082.e1.
    View in: PubMed
    Score: 0.037
  67. Equity in the receipt of oseltamivir in the United States during the H1N1 pandemic. Am J Public Health. 2014 Jun; 104(6):1052-8.
    View in: PubMed
    Score: 0.037
  68. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012 Oct 30; 60(18):1817-24.
    View in: PubMed
    Score: 0.033
  69. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013 Jan; 24(1):237-44.
    View in: PubMed
    Score: 0.032
  70. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012 May 01; 35(5):407-16.
    View in: PubMed
    Score: 0.032
  71. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012 Mar; 125(3):302.e1-7.
    View in: PubMed
    Score: 0.032
  72. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012 Mar; 60(3):420-9.
    View in: PubMed
    Score: 0.032
  73. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011 Dec 01; 365(22):2088-97.
    View in: PubMed
    Score: 0.031
  74. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011 Nov; 124(11):1081.e9-22.
    View in: PubMed
    Score: 0.031
  75. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011 May 09; 171(9):814-22.
    View in: PubMed
    Score: 0.030
  76. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011 Jun; 20(6):551-9.
    View in: PubMed
    Score: 0.030
  77. The effect of altitude change on anemia treatment response in hemodialysis patients. Am J Epidemiol. 2011 Apr 01; 173(7):768-77.
    View in: PubMed
    Score: 0.030
  78. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010 Nov 16; 153(10):633-40.
    View in: PubMed
    Score: 0.029
  79. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010 Nov; 29(11):1995-2001.
    View in: PubMed
    Score: 0.029
  80. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010 Mar 03; 303(9):857-64.
    View in: PubMed
    Score: 0.028
  81. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. Med Care. 2009 Sep; 47(9):1031-5.
    View in: PubMed
    Score: 0.027
  82. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. J Gen Intern Med. 2009 May; 24(5):570-8.
    View in: PubMed
    Score: 0.026
  83. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008; 10(4):R95.
    View in: PubMed
    Score: 0.025
  84. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.025
  85. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008 Aug; 156(2):336-41.
    View in: PubMed
    Score: 0.025
  86. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008 Jul; 156(1):31-6.
    View in: PubMed
    Score: 0.025
  87. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul; 19(7):1389-95.
    View in: PubMed
    Score: 0.024
  88. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007 Dec; 27(6):707-10.
    View in: PubMed
    Score: 0.024
  89. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007 Aug 15; 57(6):928-34.
    View in: PubMed
    Score: 0.023
  90. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007 Apr 23; 167(8):847-52.
    View in: PubMed
    Score: 0.023
  91. Performance of propensity score calibration--a simulation study. Am J Epidemiol. 2007 May 15; 165(10):1110-8.
    View in: PubMed
    Score: 0.023
  92. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood). 2007 Jan-Feb; 26(1):186-94.
    View in: PubMed
    Score: 0.022
  93. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Med Care. 2006 Jul; 44(7):658-63.
    View in: PubMed
    Score: 0.021
  94. Variable selection for propensity score models. Am J Epidemiol. 2006 Jun 15; 163(12):1149-56.
    View in: PubMed
    Score: 0.021
  95. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006; 8(3):R57.
    View in: PubMed
    Score: 0.021
  96. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005 Dec 01; 353(22):2335-41.
    View in: PubMed
    Score: 0.021
  97. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005 Oct; 25(5):427-34.
    View in: PubMed
    Score: 0.020
  98. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005 Aug; 46(2):225-32.
    View in: PubMed
    Score: 0.020
  99. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005 Aug 01; 162(3):279-89.
    View in: PubMed
    Score: 0.020
  100. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension. 2005 Aug; 46(2):273-9.
    View in: PubMed
    Score: 0.020
  101. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005 May 01; 161(9):891-8.
    View in: PubMed
    Score: 0.020
  102. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004 Nov 18; 351(21):2187-94.
    View in: PubMed
    Score: 0.019
  103. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.